Seminars in Oncology
Volume 32, Issue 1 , Pages 35-42 , February 2005

Chemotherapy for advanced colorectal cancer: Let’s not forget how we got here (until we really can)

  • Bert H. O’Neil

      Affiliations

    • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
    • Corresponding Author InformationAddress reprint requests to Bert H. O’Neil, MD, Assistant Professor of Medicine, UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB #7305, Chapel Hill, NC 27599-7305.
    • ,
  • Richard M. Goldberg

      Affiliations

    • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

References 

  1. Taguchi T , Wakui A , Hasegawa K , et al.  Research group of CPT-11   Phase I clinical study of CPT-11 . Gan To Kagaku Ryoho . 1990;17:115–120
  2. Rothenberg ML , Kuhn JG , Burris HA , et al.   Phase I and pharmacokinetic trial of weekly CPT-11 . J Clin Oncol . 1993;11:2194–2204
  3. Caussanel JP , Levi F , Brienza S , et al.   Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate . J Natl Cancer Inst . 1990;82:1046–1050
  4. Levi F , Misset JL , Brienza S , et al.   A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer . Cancer . 1992;69:893–900
  5. Rothenberg ML , Eckardt JR , Kuhn JG , et al.   Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer . J Clin Oncol . 1996;14:1128–1135
  6. Rougier P , Bugat R , Douillard JY , et al.   Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy . J Clin Oncol . 1997;15:251–260
  7. Shimada Y , Yoshino M , Wakui A , et al.  CPT-11 Gastrointestinal Cancer Study Group   Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer . J Clin Oncol . 1993;11:909–913
  8. Machover D , Diaz-Rubio E , de Gramont A , et al.   Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines . Ann Oncol . 1996;7:95–98
  9. Bertheault-Cvitkovic F , Jami A , Ithzaki M , et al.   Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer . J Clin Oncol . 1996;14:2950–2958
  10. Douillard JY , Cunningham D , Roth AD , et al.   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer (A multicentre randomised trial) . Lancet . 2000;355:1041–1047
  11. Saltz LB , Cox JV , Blanke C , et al.  Irinotecan Study Group   Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer . N Engl J Med . 2000;343:905–914
  12. de Gramont A , Figer A , Seymour M , et al.   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  13. Grothey A , Deschler B , Kroening H , et al.   Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA+ oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) . Proc Am Soc Clin Oncol . 2002;21:129a; (abstr 512)
  14. Goldberg RM , Sargent DJ , Morton RF , et al.   A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer . J Clin Oncol . 2004;22:23–30
  15. Rothenberg ML , Meropol NJ , Poplin EA , et al.   Mortality associated with irinotecan plus bolus fluorouracil/leucovorin (Summary findings of an independent panel) . J Clin Oncol . 2001;19:3801–3807
  16. Tournigand C , Andre T , Achille E , et al.   FOLFIRI followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer (A randomized GERCOR Study) . J Clin Oncol . 2004;22:229–237
  17. Colucci G , Maiello E , Paoletti G , et al.   Fluorouracil (FU) plus folinic acid (FA) with irinotecan (CPT-11) or oxaliplatin (OHP) in advanced colorectal cancer (ACC) patients (Preliminary safety results of a randomized phase III multicenter trial of the Gruppo Oncologico Italia Meridionale (GOIM)) . Proc Am Soc Clin Oncol . 2002;21:164a; (abstr 652)
  18. Comella P , Farris A , Lorusso V , et al.   Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma . Br J Cancer . 2003;89:992–996
  19. Fyfe GA , Hurwitz H , Fehrenbacher L , et al.   Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups . Proc Am Soc Clin Oncol . 2003;22: (abstr 3617)
  20. Andre T , Figer A , Cervantes A , et al.   FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study . Proc Am Soc Clin Oncol . 2003;22: (abstr 1016)
  21. Maughan TS , James RD , Kerr DJ , et al.   Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer (A multicentre randomised trial) . Lancet . 2003;361:457–464
  22. Goetz MP , Erlichman C , Windebank AJ , et al.   Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors . J Clin Oncol . 2003;21:3761–3769
  23. Souglakos J , Mavroudis D , Kakolyris S , et al.   Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer (A multicenter phase II trial) . J Clin Oncol . 2002;20:2651–2657
  24. Falcone A , Masi G , Allegrini G , et al.   Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin (A pilot study in patients with metastatic colorectal cancer) . J Clin Oncol . 2002;20:4006–4014
  25. Stein BN , Petrelli NJ , Douglass HO , et al.   Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial . Cancer . 1995;75:11–17
  26. Popescu RA , Norman A , Ross PJ , et al.   Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older . J Clin Oncol . 1999;17:2412–2418
  27. Mabro M , Gilles-Amar V , Louvet C , et al.   [Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients] . Rev Med Interne . 1999;20:863–868
  28. Jacobson SD , Cha S , Sargent DJ , et al.   Tolerability, dose intensity, and benefit of 5FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) study . Proc Am Soc Clin Oncol . 2002;21: (abstr 1534)
  29. Chiara S , Nobile MT , Vincenti M , et al.   Advanced colorectal cancer in the elderly (Results of consecutive trials with 5-fluorouracil-based chemotherapy) . Cancer Chemother Pharmacol . 1998;42:336–340
  30. Aparicio T , Desrame J , Lecomte T , et al.   Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly . Br J Cancer . 2003;89:1439–1444
  31. Taylor EC , Kuhnt D , Shih C , et al.   A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase . J Med Chem . 1992;35:4450–4454
  32. Vogelzang NJ , Rusthoven JJ , Symanowski J , et al.   Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma . J Clin Oncol . 2003;21:2636–2644
  33. Scagliotti GV , Shin DM , Kindler HL , et al.   Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma . J Clin Oncol . 2003;21:1556–1561
  34. Niyikiza C , Baker SD , Seitz DE , et al.   Homocysteine and methylmalonic acid (Markers to predict and avoid toxicity from pemetrexed therapy) . Mol Cancer Ther . 2002;1:545–552
  35. Rinaldi DA , Burris HA , Dorr FA , et al.   Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation . J Clin Oncol . 1995;13:2842–2850
  36. John W , Picus J , Blanke CD , et al.   Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma (Results from a phase II study) . Cancer . 2000;88:1807–1813
  37. Raymond E , Louvet C , Tournigand C , et al.   Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells . Int J Oncol . 2002;21:361–367
  38. Atkins JN , Jacobs S , Wieand S , et al.   Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer (A phase II trial of the NSABP foundation research program) . Proc Am Soc Clin Oncol . 2003;22: (abstr 1108)
  39. Kroening H , Hochster H , Grothey A , et al.   Pemetrexed and irinotecan as second-line therapy for locally advanced or metastatic colorectal cancer (A phase I dose escalation study) . Proc Am Soc Clin Oncol . 2003;22: (abstr 1459)
  40. Linn SC , Giaccone G . MDR1/P-glycoprotein expression in colorectal cancer . Eur J Cancer . 1995;31A:1291–1294
  41. Bollag DM , McQueney PA , Zhu J , et al.   Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action . Cancer Res . 1995;55:2325–2333
  42. Lee FY , Borzilleri R , Fairchild CR , et al.   BMS-247550 (A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy) . Clin Cancer Res . 2001;7:1429–1437
  43. Rothermel J , Wartmann M , Chen T , et al.   EPO906 (epothilone B) (A promising novel microtubule stabilizer) . Semin Oncol . 2003;30(suppl 6):51–55
  44. Eng C , Kindler HL , Skoog L , et al.   The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal cancer (CRC) . Proc Am Soc Clin Oncol . 2003;22: (abstr 1134)
  45. Poplin E , Moore M , O’Dwyer P , et al.   Safety and efficacy of EPO906 in patients with advanced colorectal cancer (A review of 2 phase II trials) . Proc Am Soc Clin Oncol . 2003;22: (abstr 1135)
  46. Yoshinari T , Ohkubo M , Fukasawa K , et al.   Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I . Cancer Res . 1999;59:4271–4275
  47. Yamada Y , Yamamoto N , Shimoyama T , et al.   Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days . Proc Am Soc Clin Oncol . 2002;21: (abstr 385)
  48. Peck R . Phase I trial of J-107088, a novel topoisomerase I Inhibitor, administered Once Every 21 Days . Proc Am Soc Clin Oncol . 2000;19: (abstr 767)
  49. Lewis L , Perez R , Petros W , et al.   A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule . Proc Am Soc Clin Oncol . 2000;19: (abstr 688)
  50. Nahum K , Shiba D , Padavanija P , et al.   Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naïve metastatic colorectal cancer (MCRC) . Proc Am Soc Clin Oncol . 2003;22: (abstr 1099)
  51. Rodriguez GI , Jones RE , Orenberg EK , et al.   Phase I clinical trials of tezacitabine [(E)-2′-deoxy-2′-(fluoromethylene)cytidine] in patients with refractory solid tumors . Clin Cancer Res . 2002;8:2828–2834
  52. Brooks DJ , Cox J , Berman BS , et al.   Phase 2 study of tezacitabine in subjects with advanced/recurrent colorectal cancer . Proc Am Soc Clin Oncol . 2003;22: (abstr 1122)
  53. Ryan DP , Clark JW , Kulke MH , et al.   A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer . Cancer Invest . 2003;21:505–511
  54. Pitot HC , Wiesenfeld M , Mahoney M , et al.   A phase II trial of oxaliplatin (Oxal), 5-fluorouracil (5Fu), and leucovorin (LV) in patients (pts) with metastatic colon cancer (M-CRC) refractory to irinotecan (CPT11) based therapy (A North Central Cancer Treatment Group (NCCTG) study) . Proc Am Soc Clin Oncol . 2003;22:261; (abstr 1048)
  55. Tournigand C , Louvet C , Quinaux E , et al.   FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC) (Final results of a phase III study) . Proc Am Soc Clin Oncol . 2001;20: (abstr 494)
  56. Rougier P , Lepille D , Bennouna J , et al.   Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure (A randomised, multicentre phase II study) . Ann Oncol . 2002;13:1558–1567
  57. Rothenberg ML , Oza AM , Bigelow RH , et al.   Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin (Interim results of a phase III trial) . J Clin Oncol . 2003;21:2059–2069
  58. Rothenberg ML , Oza AM , Burger B , et al.   Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin . Proc Am Soc Clin Oncol . 2003;22: (abstr 1011)
  59. Grothey A , Sargent D , Goldberg RM , et al.   Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment . J Clin Oncol . 2004;22:1209–1214

PII: S0093-7754(04)00459-2

doi: 10.1053/j.seminoncol.2004.09.030

Seminars in Oncology
Volume 32, Issue 1 , Pages 35-42 , February 2005

Article Tools